RAGE signaling regulates the progression of diabetic complications
Open Access
- 16 March 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1128872
- https://doi.org/10.3389/fphar.2023.1128872
Abstract
Diabetes, the ninth leading cause of death globally, is expected to affect 642 million people by 2040. With the advancement of an aging society, the number of patients with diabetes having multiple underlying diseases, such as hypertension, obesity, and chronic inflammation, is increasing. Thus, the concept of diabetic kidney disease (DKD) has been accepted worldwide, and comprehensive treatment of patients with diabetes is required. Receptor for advanced glycation endproducts (RAGE), a multiligand receptor, belonging to the immunoglobulin superfamily is extensively expressed throughout the body. Various types of ligands, including advanced glycation endproducts (AGEs), high mobility group box 1, S100/calgranulins, and nucleic acids, bind to RAGE, and then induces signal transduction to amplify the inflammatory response and promote migration, invasion, and proliferation of cells. Furthermore, the expression level of RAGE is upregulated in patients with diabetes, hypertension, obesity, and chronic inflammation, suggesting that activation of RAGE is a common denominator in the context of DKD. Considering that ligand- and RAGE-targeting compounds have been developed, RAGE and its ligands can be potent therapeutic targets for inhibiting the progression of DKD and its complications. Here, we aimed to review recent literature on various signaling pathways mediated by RAGE in the pathogenesis of diabetic complications. Our findings highlight the possibility of using RAGE- or ligand-targeted therapy for treating DKD and its complications.This publication has 142 references indexed in Scilit:
- Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptorCardiovascular Diabetology, 2013
- FGF Regulates TGF-β Signaling and Endothelial-to-Mesenchymal Transition via Control of let-7 miRNA ExpressionCell Reports, 2012
- Pentosidine as a biomarker for microvascular complications in type 2 diabetic patientsDiabetes and Vascular Disease Research, 2012
- Receptor for Advanced Glycation End Products (RAGE) Prevents Endothelial Cell Membrane Resealing and Regulates F-actin Remodeling in a β-Catenin-dependent MannerOnline Journal of Public Health Informatics, 2011
- Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeuticsAmino Acids, 2010
- Rapid glycation with D-ribose induces globular amyloid-like aggregations of BSA with high cytotoxicity to SH-SY5Y cellsBMC Cell Biology, 2009
- Interaction of the RAGE Cytoplasmic Domain with Diaphanous-1 Is Required for Ligand-stimulated Cellular Migration through Activation of Rac1 and Cdc42Online Journal of Public Health Informatics, 2008
- The FGF system has a key role in regulating vascular integrityJCI Insight, 2008
- Role of Advanced Glycation End Products With Oxidative Stress in Resistance Artery Dysfunction in Type 2 Diabetic MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEsAmerican Journal of Physiology-Endocrinology and Metabolism, 2008